Yoon HJ, Kim BS, Jeong JH, et al. - In the present study, the researchers sought to examine changes in brain perfusion and Aβ burden according to the progression of Alzheimer disease (AD) by utilizing a dual-phase ¹⁸ F-Florbetaben (FBB) PET protocol. Sixty individuals were enrolled, including 12 with Aβ-negative normal cognition (Aβ-NC), 32 with Aβ-positive mild cognitive impairment (Aβ+MCI), and 16 with Aβ-positive AD (Aβ+AD). The findings of this study showed the feasibility of using dual-phase ¹⁸ F-FBB PET to assess different trajectories of dual biomarkers for neurodegeneration and Aβ burden over the course of AD. Furthermore, both eFBB and simplified reference tissue model-based R1 can provide reliable indices of brain perfusion.